USE OF BIOMARKER(S) TO IDENTIFY A WEE1 INHIBITOR RESPONSIVE PATIENT AND METHODS OF TREATING CANCER MEDIATED BY DYSFUNCTIONAL OR ABERRANT P53 VIA ADMINISTRATION OF A WEE1 INHIBITOR

摘要

The present invention provides the identification of biomarker gene sets whose expression levels are useful for predicting a patient's response to a therapeutically effective dose of a Wee1 inhibitor as well the ability to predict said response prior to dosing with the Wee1 inhibitor. Additional uses are also disclosed in the specification.